Sofosbuvir-based antiviral therapy caused no major arrhythmias or adverse cardiac events during or after treatment in hepatitis C patients with pre-existing heart disease.
Does sofosbuvir-based antiviral therapy have a reassuring cardiac safety profile in HCV patients with pre-existing heart disease?
Sofosbuvir-based direct-acting antivirals appear to be well tolerated without major cardiac adverse events in HCV patients with pre-existing heart disease.
Absolute Event Rate: 0% vs 0%
Sofosbuvir-based antiviral therapy was well tolerated and demonstrated a reassuring cardiac safety profile in HCV patients with pre-existing heart disease, with no major arrhythmias or adverse cardiac events observed during or after therapy.
Hanafy et al. (Thu,) reported a other. Sofosbuvir-based antiviral therapy caused no major arrhythmias or adverse cardiac events during or after treatment in hepatitis C patients with pre-existing heart disease.